NCT03429998View on ClinicalTrials.gov

Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

January 28, 2018

Study Completion Date

January 28, 2018

Conditions
Hypercholesterolemia
Interventions
DRUG

evolocumab

evolocumab 140 mg/biweekly

DRUG

evolocumab and LDL apheresis

evolocumab 140 mg/biweekly LDL-apheresis monthly

PROCEDURE

LDL apheresis

LDL apheresis biweekly

Trial Locations (1)

28007

Hospital General Universitario Gregorio Marañon, Madrid

All Listed Sponsors
lead

Hospital General Universitario Gregorio Marañon

OTHER

NCT03429998 - Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia | Biotech Hunter | Biotech Hunter